搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
BioSpace
2 天
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
BioSpace
2 天
Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...
BioSpace
2 天
7 Indications for GLP-1s Beyond Weight Loss
Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...
BioSpace
2 天
To Attract VC Dollars in 2025, Biopharma Must Bring the Data: Pitchbook
High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk ...
BioSpace
5 天
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...
BioSpace
6 天
The 5 Largest Biopharma Layoffs of 2024
While layoffs have slowed in the second half of the year, according to BioSpace data, companies including Bayer, Bristol ...
BioSpace
5 天
Ionis’ Tryngolza Becomes First FDA-Approved Therapy for Familial Chylomicronemia Syndrome
Despite securing the industry’s first approval for familial chylomicronemia syndrome, BMO Capital Markets believes that ...
BioSpace
5 天
GSK Posts Mixed Survival Data for Jemperli/Zejula Combo in First-Line Ovarian Cancer
First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...
BioSpace
5 天
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data
Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...
BioSpace
2 天
5 Companies That Celebrated First Approvals in 2024
Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...
BioSpace
7 天
2024: A Year of Cautious IPOs, Restraint and Breakthroughs
Indeed, there weren’t many more biotech IPOs in 2024 than in 2023, and the companies that did venture out this year struggled ...
BioSpace
9 天
5 Clinical Assets That Flopped in 2024
Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈